S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
NASDAQ:CHFS

Nuwellis - CHFS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$4.52
▼
$5.54
50-Day Range
$3.53
▼
$6.02
52-Week Range
$4.86
▼
$37.50
Volume
305,376 shs
Average Volume
467,323 shs
Market Capitalization
$29.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CHFS stock logo

About Nuwellis (NASDAQ:CHFS) Stock

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Receive CHFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter.

CHFS Stock News Headlines

March 11, 2023 | forbes.com
Best Prenatal Vitamins Of 2023, According To Experts
February 20, 2023 | forbes.com
Best Multivitamins For Kids In 2023, According To Experts
March 20, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
October 19, 2022 | globenewswire.com
Nuwellis Announces Appointment of Chief Financial Officer - GlobeNewswire
October 18, 2022 | streetinsider.com
Form 424B4 Nuwellis, Inc. - StreetInsider.com
October 17, 2022 | uk.investing.com
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday By Benzinga - Investing.com UK
October 14, 2022 | uk.investing.com
Why Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday's Mid-Day Session By Benzinga - Investing.com UK
October 14, 2022 | benzinga.com
Why Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday’s Mid-Day Session - Agri - Benzinga
March 20, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
October 14, 2022 | uk.investing.com
Why IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket By Benzinga - Investing.com UK
October 14, 2022 | globenewswire.com
Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering - GlobeNewswire
October 4, 2022 | msn.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 2.66% - msnNOW
October 4, 2022 | streetinsider.com
Nuwellis (NUWE) Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA - StreetInsider.com
October 3, 2022 | in.investing.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 2.66% - Investing.com India
October 3, 2022 | benzinga.com
Nuwellis shares are trading higher after the company announced results of the AVOID-HF clinical study ana - Benzinga
October 3, 2022 | finance.yahoo.com
Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting - Yahoo Finance
October 3, 2022 | globenewswire.com
Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting - GlobeNewswire
September 27, 2022 | benzinga.com
Nuwellis Announces Activation Of New Sites For Its Pivotal REVERSE-HF Trial - Nuwellis (NASDAQ:NUWE) - Benzinga
September 27, 2022 | finance.yahoo.com
Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial - Yahoo Finance
September 27, 2022 | globenewswire.com
Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial - GlobeNewswire
August 31, 2022 | nasdaq.com
Health Care Sector Update for 08/31/2022: NUWE,BNR,SRNE,OSCR - Nasdaq
August 31, 2022 | benzinga.com
Nuwellis, Inc. - Common Stock (NUWE) – Nuwellis shares are trading higher after the company announced new - Benzinga
August 31, 2022 | benzinga.com
Nuwellis, Inc. - Common Stock (NUWE) – Peering Into Nuwellis's Recent Short Interest - Benzinga
August 31, 2022 | finance.yahoo.com
Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients - Yahoo Finance
August 31, 2022 | investorplace.com
Why Is Nuwellis (NUWE) Stock Up 110% Today?
August 31, 2022 | globenewswire.com
Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients - GlobeNewswire
August 25, 2022 | benzinga.com
U.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology - Benzinga
See More Headlines
Receive CHFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter.

CHFS Company Calendar

Last Earnings
3/01/2021
Today
3/20/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Electromedical Equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHFS
Previous Symbol
NASDAQ:SSH
CUSIP
N/A
CIK
1506492
Web
www.chf-solutions.com
Phone
(952) 345-4200
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($279.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,110,000.00
Net Margins
-254.26%
Pretax Margin
N/A
Return on Equity
-173.61%
Return on Assets
-131.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.87
Quick Ratio
5.97

Sales & Book Value

Annual Sales
$5.51 million
Price / Sales
5.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.79 per share
Price / Book
0.38

Miscellaneous

Outstanding Shares
6,037,000
Free Float
N/A
Market Cap
$29.04 million
Optionable
Not Optionable
Beta
1.55

Key Executives

  • Nestor Jaramillo
    President, Chief Executive Officer, CFO & Director
  • Vitaliy Epshteyn
    Senior Vice President-Operations & Engineering
  • David Lerner
    Chief Technology Officer
  • Thomas P. Lynch
    Secretary, Chief Legal & Compliance Officer
  • Laurent Duhoux
    Vice President-International Business Development

Key Competitors

View All Competitors













CHFS Stock - Frequently Asked Questions

How were Nuwellis' earnings last quarter?

Nuwellis, Inc. (NASDAQ:CHFS) issued its quarterly earnings data on Monday, March, 1st. The company reported ($1.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.91) by $0.34. The business earned $2.04 million during the quarter. Nuwellis had a negative trailing twelve-month return on equity of 173.61% and a negative net margin of 254.26%.

When did Nuwellis' stock split?

Nuwellis's stock reverse split on Friday, October 13th 2017. The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Nuwellis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nuwellis investors own include Biocept (BIOC), Immutep (IMMP), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Zosano Pharma (ZSAN), Avinger (AVGR), Co-Diagnostics (CODX), iBio (IBIO), Inovio Pharmaceuticals (INO) and Onconova Therapeutics (ONTX).

What is Nuwellis' stock symbol?

Nuwellis trades on the NASDAQ under the ticker symbol "CHFS."

What is Nuwellis' stock price today?

One share of CHFS stock can currently be purchased for approximately $4.81.

How much money does Nuwellis make?

Nuwellis (NASDAQ:CHFS) has a market capitalization of $29.04 million and generates $5.51 million in revenue each year. The company earns $-18,110,000.00 in net income (profit) each year or ($279.28) on an earnings per share basis.

How can I contact Nuwellis?

Nuwellis' mailing address is 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN, 55344. The official website for the company is www.chf-solutions.com. The company can be reached via phone at (952) 345-4200 or via email at ir@chf-solutions.com.

This page (NASDAQ:CHFS) was last updated on 3/20/2023 by MarketBeat.com Staff